Dr. Arnaout is a physician-scientist in the Department of Medicine at Massachusetts General Hospital in Boston. He is Chief-Emeritus of the Division of Nephrology at Massachusetts General Hospital, and Professor of Medicine at Harvard Medical School.
- Centers & Specialties
- Clinical Interests
- Inflammatory kidney diseases
- Polycystic kidney disease
- Acute renal failure
- End Stage Renal Disease
- Medical Education
- MD, American University of Beirut
- Residency, The Johns Hopkins Hospital
- Fellowship, Boston Children's Hospital|Fellowship, Brigham and Women's Hospital
- Board Certifications
- Internal Medicine
- Foreign Languages
- Boston: Massachusetts General Hospital
- Existing Patients
- Patient Gateway
- Insurances Accepted
- Aetna Health Inc.
- AllWays Health (NHP) - ACD
- AllWays Health (NHP) - PBO
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- BMC HealthNet Mass Health MCO/ACO
- Cigna (PAL #'s)
- Commonwealth Care Alliance
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Maine Community Health Options (MCHO)
- Medicare - ACD
- OSW - Maine
- OSW - New Hampshire
- OSW - Rhode Island
- Private Health Care Systems (PHCS)
- Railroad Medicare
- Railroad Medicare - ACD
- Senior Whole Health
- Tufts Health Plan
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
- Well Sense Pediatrics
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
- Patient Age Group
- Provider Gender
- Research Summary
Our laboratoryis interested in elucidating the molecular basis of human disease and in usingthis information to guide development of new and safer therapies. We utilizestate of the art technologies, including genetics, genomics, biochemistry, cellbiology, structural and computational biology and animal models of disease. Areas of interest include integrinbiology and structure, pathogenesis of autosomal dominant polycystic kidneydisease, lineage commitment in hematopoietic stem cells, mechanisms of ischemic kidney injuryand regeneration and engineering kidney assistdevices.
- Arnaout MA, Hakim RM, Todd RF, Dana N, Colten HR.1985. Increased expression of an adhesion-promoting surface glycoprotein in the granulocytopenia of hemodialysis. N Engl J Med. 312:457.
- Michishita M, Videm V, Arnaout MA. 1993. A novel divalent cation-binding site in the A- domain of the beta 2 integrin CR3 (CD11b/CD18) is essential for ligand binding. Cell. 72: 857.
- Lee JO, Rieu P, Arnaout MA (Corresp. author), Liddington R. 1995. Crystal structure of the A domain of the alpha subunit of integrin CR3 (CD11b/CD18). Cell. 80:631.
- Gonzalez-Perrett S, Kim K, Ibarra C, Damiano AE, Zotta E, Batelli M, Harris PC, Reisin IL, Arnaout MA, Cantiello HF. 2000. Polycystin-2, the protein mutated in autosomal dominant Polycystic Kidney Disease (ADPKD), is a Ca2+-permeable non-selective cation channel. Proc. Natl Acad. Sci. USA. 98:1182.
- Xiong JP, Stehle T, Diefenbach B, Zhang R, Dunker R, Scott DL, Joachimiak A, Goodman SL, Arnaout MA. 2001. Crystal structure of the extracellular segment of integrin alphaV/beta3. Science. 294:339.
- Xiong JP, Stehle T, Zhang R, Dunker R, Joachimiak A, Frech M, Goodman SL, Arnaout MA. 2002. Crystal structure of the extracellular domain of integrin alphaV/beta3 in complex with an Arg-Gly-Asp Ligand. Science. 296:151.
- Van Agthoven JF, Xiong JP, Rui X, Alonso JL, Adair BD, Goodman SL, Arnaout MA. 2014. Structural basis for prue antagonism of alphaV/beta3 by a high affinity form of fibronectin. Nature Struc Mol Biol 21:383.
A Massachusetts General Hospital research team, using the kidney as an example, has developed a way to avoid ischemia/reperfusion injury with a new monoclonal antibody that binds its target in a way that is "just right."
MGH investigators may have found a way to solve a problem that has plagued a group of drugs called ligand-mimicking integrin inhibitors, which have the potential to treat conditions ranging from heart attacks to cancer metastasis.
165 Cambridge Street
Boston, MA 02114-2752
Phone 1: 617-726-5050
Phone 2: 617-726-5663